Oppenheimer Initiates Coverage On Capricor Therapeutics with Outperform Rating, Announces Price Target of $14
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Capricor Therapeutics (NASDAQ:CAPR) with an Outperform rating and a price target of $14.
May 17, 2024 | 9:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Capricor Therapeutics with an Outperform rating and a price target of $14.
The initiation of coverage with an Outperform rating and a price target of $14 by a reputable firm like Oppenheimer is likely to positively impact the stock price of Capricor Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100